FDA jurisdiction still unchallenged – but industry presses for clarity

The US Food and Drug Administration is moving slowly in drawing regulatory boundaries for CBD businesses. Members of Congress have called for clarity, but the FDA says it has no plans to give cannabis derivatives the green light ...

Restricted content. Do you want to read more?